Updated Results of the PATH Study: Adjuvant Therapy with Donafenib Plus a PD-1 Inhibitor for Patients with Hepatocellular Carcinoma at High Risk of Recurrence after Resection.
Journal of Clinical Oncology（2025）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要